1. Kathryn J. Ruddy, David Zahrieh, Jun He, Blake Waechter, Julianne L. Holleran3, Lionel D. Lewis, Selina Chow, Jan Beumer, Matthias Weiss, Nikolaos Trikalinos, Bryan Faller, Maryam Lustberg, Hope S. Rugo, Charles Loprinzi. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). THIS ISSUE OF SEMINARS IN ONCOLOGY
2. Is There Room for Improvement in Adverse Event Reporting in the Era of Targeted Therapies?;Edgerly;J Natl Cancer Inst,2008
3. Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients;Prasad;J Clin Oncol,2014
4. Everolimus in Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer;Baselga;N Engl J Med,2012
5. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2;Piccart;Ann Oncol,2014